Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
100
Views
11
CrossRef citations to date
0
Altmetric
Review

Novel therapies in transplantation

Anamaria Jorga Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK
&
Atholl Johnston Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK. [email protected]
Pages 295-304 | Published online: 22 Apr 2005

Bibliography

  • KOVARIK JM, BURTIN P: Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Ernerg. Drugs (2003) 8(1):47–62.
  • ••A recent review that discusses newimmunosuppressant drugs and their impact on the market.
  • VINCENTI F: New monoclonal antibodies in renal transplantation. Minerva Urol. Nefrol (2003) 55(1):57–66.
  • JORGA A, JOHNSTON A, HOLT DW: Patient management by cyclosporine C2 monitoring. Transplantation (2004) 77(2):323–324.
  • JOHNSTON A, HOLT DW: Immunosuppressant drugs-the role of therapeutic drug monitoring. Br. J. Clin. Pharmacol (2001) 52\(Suppl. 1):615–735.
  • JORGA A, HOLT DW, JOHNSTON A: Therapeutic drug monitoring of cyclosporine. Transplant Proc. (2004) 36\(Supp1.2):396S–403S.
  • SAYEGH MH, TURKA LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl. J. Med. (1998) 338(25):1813–1821.
  • PELLETIER RP, AKIN B, HENRY ML et al: The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant (2003) 17(3):200–205.
  • SALVADORI M, HOLZER H, DE MATTOS A et al.: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. Transplant. (2004) 4(2):231–236.
  • BUDDE K, CURTIS J, KNOLL G et al: Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. (2004) 4(2):237–243.
  • ASPESLET L, FREITAG D, TREPANIER D et al: ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc. (2001) 33(1-2):1048–1051.
  • STALDER M, BIRSAN T, HUBBLE RW, PANIAGUA RT, MORRIS RE: In vivo evaluation of the novel calcineurin inhibitor I5ATX247 in non-human primates. Heart Lung Transplant (2003) 22(12):1343–1352.
  • GREGORY CR, KYLES AE, BERNSTEEN L et al: Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation (2004) 78(5):681–685.
  • ABEL MD: Phase I evaluation of a novel calcineurin inhibitor I5Atx247. Am. J. Transplant (2003) 1 AD (Abstract).
  • Isotechika press release: final results of Phase Ha kidney transplant trial at American Transplant Congress (2003).
  • ABEL M: Phase II trial results of ISAtx247, a novel calcineurin inhibitor in renal transplantation. Am. J. Transplant. (2004) 3\(Suppl. 2):379 (Abstract).
  • DUMONT FJ: ISAtx-247 (Isotechnika/Roche). Curr. Opin. Investig. Drugs (2004) 5(5):542–550.
  • NASHAN B:, CURTIS J, PONTICELLI C, MOURAD G, JAFFE J, HAAS T: Everolimus and reduced-exposure cyclosporine in de novo renal transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation (2004) 78(9) 1332–1340.
  • KAHAN BD, KAPLAN B, LORBER MI et al: RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71(10):1400–1406.
  • VITKO MARGARGREITER R WW: Everolimus (CerticanTm) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (2004)
  • MOURAD G:, NASHAN B, CURTIS J et al: Certican (RAD, everolimus) the proliferation signal, is complementary with reduced dose Neoral based quadruple immunosuppressive regime. A transplant Odyssey The future is here. Turkey (2001):S18.1 (Abstract).
  • EISEN HJ, TUZCU EM, DORENT R et al: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl. Med. (2003) 349(9):847–858.
  • KOVARIK JM, KAPLAN B, TEDESCO SH et al: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 73(6):920–925.
  • KAHAN BD: FTY-720 in combination with RAD: a calcineurin antagonist-free maintenance immunosupression strategy. 2001:A transplant odyssey The future is here. (2004): S12.5.
  • KAHAN BD:FTY720: from bench to bedside. Transplant Proc.(2004)36\(Suppl. 2):5315–5435.
  • KAHAN BD: Update on pharmacokineticipharmacodynamic studies with FTY720 and sirolimus. Ther. Drug Monit. (2002) 24(1):47–52.
  • BUDDE K, SCHMOUDER RL, BRUNKHORST R et al: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. I Am. Soc. Nephrol (2002) 13(4):1073–1083.
  • BUDDE K, SCHMOUDER L, NASHAN B et al.: Pharmacodynamics of single doses of the novel immunosuppressant FTY-720 in stable renal transplant patients. Am. J. Transplant. (2003) 3(7):846–854.
  • KAHAN BD, KARLIX JL, FERGUSON RIVI et al: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, Phase I study. Transplantation (2003) 76(7):1079–1084.
  • TEDESCO-SILVA H, MOURAD G, KAHAN BD et al: FTY720, a novel immunomodulator: efficacy and safety results from the first Phase IIA study in de novo renal transplantation. Transplantation (2004) 77(12):1826–1833.
  • •An open-label, dose-finding Phase Ha study in which FTY-720 0.25, 0.5, 1 or 2.5 mg/day was compared with MMF in a total of 208 de novo patients.
  • FERGUSON RM, MULGAONKAR S, TEDESCO-SILVA H: FTY-720 with reduced exposure Neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Transplantation (2002) (Abstract).
  • •A study in 266 kidney patients, in which 2.5 mg/day of FTY-720 was combined with either reduced- or full-dose cyclosporin for comparison with full-dose cyclosporin and MME The BPAR rates were similar in all groups whether treated with FTY-720 and a reduced-dose of cyclosporin (9.6%) or full-dose cyclosporin and FTY-720 (8.5%) or full-dose cyclosporin and MMF (7.9%).
  • BIRSAN T, DAMBRIN C, KLUPP J et al: Effects of the malononitrilamide FK-778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl. Immunol (2003) 11(2):163–167.
  • SLAUSON SD, SILVA HT, SHERWOOD SW, MORRIS RE: Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett. (1999) 67(3):179–183.
  • DEUSE T, SCHREPFER S, REICHENSPURNER H: Immunosuppression with FK-778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation (2003) 76(11):1627–1629.
  • BILOLO KK, OUYANG J, WANG X et al.: Synergistic effects of malononitrilamides (FK-778, FK-779) with tacrolimus (FK-506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation (2003) 75(11):1881–1887.
  • QI S, ZHU S, XU D et al: Significant prolongation of renal allograft survival by delayed combination therapy of FK-778 with tacrolimus in nonhuman primates. Transplantation (2003)75(8):1124–1128.
  • VINCENTI F: What's in the pipeline? New immunosuppressive drugs in transplantation. Am. I Transplant (2002) 2 (10):898–903.
  • ••A review that describes newimmunosuppressants, focusing on the novel mechanisms of actions.
  • VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, VANRENTERGHEM Y, PACZEK L: A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation (2003) 75(12):1934–1939.
  • CIANCIO G, BURKE GW, SUZART K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 73(7):1100–1106.
  • VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, VANRENTERGHEM Y, PACZEK L: A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation (2003) 75(12):1934–1939.
  • DUMONT FJ: Alemtuzumab (Millennium/ILEX). Curr. Opin. Investig. Drugs (2001) 2(1):139–160.
  • ••A comprehensive review of a new drugalemtuzumab in the treatment of autoimmune diseases and transplantation.
  • KNECHTLE SJ: Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr. Transplant (2004) 8(2):106–112.
  • CALNE R: 'Almost tolerance' in the clinic. Transplant Proc. (1998) 30(7):3846–3848.
  • CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68(10):1613–1616.
  • ••This study describes acceptable results andallowed patients to be steroid free and maintained on a very low dose of cyclosporin therapy when alemtuzumab is administered.
  • KNECHTLE SJ, FERNANDEZ LA, PIRSCH JD et al: Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery (2004) 136(4):754–760.
  • CIANCIO G, BURKE GW, GAYNOR JJ et al: The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 78(3):426–433.
  • MARCOS A, EGHTESAD B, FUNG JJ et al.: Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 78(7):966–971.
  • TZAKIS AG, KATO T, NISHIDA S et al: Preliminary experience with campath 1H (Cl H) in intestinal and liver transplantation. Transplantation (2003) 75(8):1227–1231.
  • TZAKIS AG, TRYPHONOPOULOS P, KATO T et al.: Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 77(8):1209–1214.
  • TZAKIS AG, KATO T, NISHIDA S et al: Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 75(9):1512–1517.
  • WATSON CJ, FIRTH J, BRADLEY JR et al: Campath 1H (alemtuzumab) in renal transplantation: 5 year comparative follow up. Transplantation (2004) 78(2):55 (Abstract).
  • BASU A: Reversal of acute cellular rejection (ACR) using the monoclonal antibody Campath 1H. Tranplantation 4AD. (Abstract)
  • HALE G: Alemtuzumab in stem cell transplantation. Med. Oncol. (2002) 19(Suppl.):S33–S47.
  • CALNE RY: The future of organ transplantation: from the laboratory to the clinic. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1409):767–771.
  • DUMONT FJ: Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. (2004) 6(3):318–330.
  • BARTLETT AS, McCALL JL, AMERATUNGA R et al.: Costimulatory blockade prevents early rejection, promotes lymphocyte apoptosis, and inhibits the upregulation of intragraft interleukin-6 in an orthotopic liver transplant model in the rat. Liver Transpl. (2002) 8(5):458–468.
  • DONG VM, YUAN X, COITO AJ et al: Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation (2002) 73(8):1310–1317.
  • NASHAN B: Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and CV metabolic profile at 6 months compared with cyclosporine. Am. J. Transplant. (2004) 4\(Suppl. 8):441.

Websites

  • http://www.uktransplantorg.uk UK Transplant Activity Report 2003-2004
  • http://www.nice.org.uk Renal transplantation - immuno- suppressive regimens (adults) (No. 85).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.